Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 8/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475737 | 0.95 | POLB (0.55) | POLBTP53PIK3C3SMN1; SMN2ALDH1A1 | |
| SCHEMBL1583553 | 0.90 | TP53 (0.52) | POLBTP53PIK3C3SMN1; SMN2ALDH1A1 | |
| SCHEMBL13229564 | 0.90 | POLB (0.60) | POLBTP53BACE1PIK3C3SMN1; SMN2 | |
| SCHEMBL5223342 | 0.87 | POLB (0.50) | POLBTP53PIK3C3SMN1; SMN2ALDH1A1 | |
| SCHEMBL3889341 | 0.86 | POLB (0.49) | POLBTP53PIK3C3SMN1; SMN2ALDH1A1 | |
| SCHEMBL5218542 | 0.86 | POLB (0.49) | POLBTP53PIK3C3SMN1; SMN2ALDH1A1 | |
| SCHEMBL18767065 | 0.85 | POLB (0.54) | POLBTP53BACE1PIK3C3SMN1; SMN2 | |
| SCHEMBL3886939 | 0.85 | POLB (0.64) | POLBTP53BACE1PIK3C3 | |
| SCHEMBL5379341 | 0.84 | TP53 (0.48) | POLBTP53PIK3C3SMN1; SMN2ALDH1A1 | |
| SCHEMBL5901042 | 0.83 | TP53 (0.48) | POLBTP53SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-7476764-B2 | Phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-13 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032470-A1 | Novel phenylcarboxyamides as beta-secretase inhibitors | BACE1, APP, BACE2 | POLB 3403/4885TP53 3617/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.